Author:
Rosli Naim Asyraf,Al-Maleki Anis Rageh,Loke Mun Fai,Chua Eng Guan,Alhoot Mohammed Abdelfatah,Vadivelu Jamuna
Abstract
Abstract
Background
Clarithromycin-containing triple therapy is commonly used to treat Helicobacter pylori infections. Clarithromycin resistance is the leading cause of H. pylori treatment failure. Understanding the specific mutations that occur in H. pylori strains that have evolved antibiotic resistance can help create a more effective and individualised antibiotic treatment plan. However, little is understood about the genetic reprogramming linked to clarithromycin exposure and the emergence of antibiotic resistance in H. pylori. Therefore, this study aims to identify compensatory mutations and biofilm formation associated with the development of clarithromycin resistance in H. pylori. Clarithromycin-sensitive H. pylori clinical isolates were induced to develop clarithromycin resistance through in vitro exposure to incrementally increasing concentration of the antibiotic. The genomes of the origin sensitive isolates (S), isogenic breakpoint (B), and resistant isolates (R) were sequenced. Single nucleotide variations (SNVs), and insertions or deletions (InDels) associated with the development of clarithromycin resistance were identified. Growth and biofilm production were also assessed.
Results
The S isolates with A2143G mutation in the 23S rRNA gene were successfully induced to be resistant. According to the data, antibiotic exposure may alter the expression of certain genes, including those that code for the Cag4/Cag protein, the vacuolating cytotoxin domain-containing protein, the sel1 repeat family protein, and the rsmh gene, which may increase the risk of developing and enhances virulence in H. pylori. Enhanced biofilm formation was detected among R isolates compared to B and S isolates. Furthermore, high polymorphism was also detected among the genes associated with biofilm production.
Conclusions
Therefore, this study suggests that H. pylori may acquire virulence factors while also developing antibiotic resistance due to clarithromycin exposure.
Funder
Ministry of Higher Education, Malaysia
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology,Gastroenterology,Microbiology,Parasitology
Reference72 articles.
1. Crowe SE. Helicobacter pylori infection. NEJM. 2019;380:1158–65.
2. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719-31.e3.
3. Vieira RR, Fontes LES, Pacheco RL, Fernandes MAP, Malta PP, Riera R. Proton pump inhibitor- and clarithromycin-based triple therapies for Helicobacter pylori eradication. CDSR. 2020. https://doi.org/10.1002/14651858.CD013734.
4. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review Article: the global emergence of Helicobacter pylori antibiotic resistance. AP&T. 2016;43:514–33.
5. Puah SM, Goh KL, Ng HK, Chua KH. Current status of Helicobacter pylori resistance to clarithromycin and levofloxacin in Malaysia—findings from a molecular based study. PeerJ. 2021;9: e11518.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献